Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1535576
Reference Type
Journal Article
Title
Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Author(s)
De Rosa, S; Cirillo, P; Pacileo, M; Petrillo, G; D'Ascoli, GL; Maresca, F; Ziviello, F; Chiariello, M
Year
2011
Is Peer Reviewed?
Yes
Journal
Current Vascular Pharmacology
ISSN:
1570-1611
Volume
9
Issue
2
Page Numbers
188-199
PMID
21143176
DOI
10.2174/157016111794519372
Web of Science Id
WOS:000288984600009
Abstract
Inflammation plays a role at all stages of atherosclerosis.
Neopterin, a pteridine mainly synthesized by activated macrophages, is a marker of inflammation,
immune system activation and an active participant in cardiovascular disease. Measurement of
neopterin levels may help follow the evolution of specific inflammatory conditions (e. g. viral
infection, renal transplant rejection, systemic inflammatory diseases, nephritic syndrome and
autoimmune diseases). Serum levels of neopterin are elevated also in patients with coronary
artery disease (CAD) and peripheral artery disease (PAD). Moreover, plasma levels of this
molecule might predict adverse cardiovascular events in patients with CAD, acute coronary
syndromes or severe PAD. In addition, neopterin levels are related to the development of heart
failure. We provide an updated overview on neopterin and, its links with CAD, left ventricular
dysfunction, and PAD. We also describe its potential role in cardiac regenerative strategies with
using bone marrow cells.
Keywords
Atherosclerosis; cardiovascular disease; inflammation; neopterin
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity